Drug factory · FDA FEI 3002807919
Curia Italy S.r.l.
Via Volturno 41/43, Rozzano, Italy
Problems found, fixed voluntarily at FDA's last inspection, Sep 16, 2022.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
5 drug inspections on record since 2011: 1 with no problems, 4 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Bromocriptine | Makes the active ingredient | Avvisto Therapeutics LLC | 73515-123 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Sep 16, 2022 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jan 25, 2019 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Mar 31, 2017 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Feb 5, 2015 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Sep 15, 2011 | No problems found | Drug Quality Assurance | — |
Registered with FDA for: analysis; api manufacture.